Abstract
Emerging SARS-CoV-2 variants of concern/interest (VOC/VOI) raise questions about effectiveness of neutralizing antibodies derived from infection or vaccination. Here, we have assessed a total of 104 blood specimens, consisting of convalescent samples after infection with early-pandemic SARS-CoV-2 (pre-VOC) or with Alpha, Beta, Gamma or Delta, post-vaccination samples after double-dose mRNA-vaccination as well as samples after vaccine break-through infections with Delta or Omicron. Neutralization against seven authentic SARS-CoV-2 isolates (B.1, Alpha, Beta, Gamma, Delta, Zeta, Omicron) was assessed by plaque-reduction neutralization assay.
We found highest neutralization titers against the homologous (previously infecting) variant, with lower neutralization efficiency against heterologous variants. Loss of neutralization against heterologous variants showed considerably variability between convalescent groups suggesting that a variant-specific infection background influences immune escape characteristics.
Convalescent samples from pre-VOC SARS-CoV-2, Alpha, Beta, Gamma and Delta-infected individuals all showed a significant loss of neutralization for Omicron but to a varying degree (23.0-fold in Beta-convalescent up to 56.1-fold in Alpha-convalescent samples), suggesting that infection-derived immunity, independent of the infecting variant is most likely only poorly protective against Omicron. Of note, former variant of concern Zeta showed also a pronounced escape form neutralization of up to 28.2-fold in Alpha convalescent samples.
Two-dose vaccinated individuals showed robust neutralization against B.1 and only slightly lower neutralization titers for Alpha, Beta, Gamma, Delta and Zeta, with fold-change reduction for heterologous virus between 2.8 (for Alpha) to 6.9 (for Beta). In contrast to convalescent specimens, escape from neutralization for Zeta was largely restored in vaccinated individuals, while Omicron showed a strongly reduced neutralization of 85.7-fold compared to pre-VOC SARS-CoV-2.
Robust neutralization titers were observed in double-vaccinated individuals with subsequent Delta break-through infections, that also neutralized Omicron with a loss of only 12.5-fold. Individuals with an Omicron breakthrough infection showed high neutralization titers for both Delta and Omicron, with only a 1.5-fold loss for Delta neutralization. This suggests that infection with antigenically different variants can boost immunity against variants that are antigenically similar to the vaccine strain.
We conclude that for the assessment of escape from neutralization by new VOCs such as Omicron, the complexity of background immunity due to individual and regional differences needs to be taken into account. Geographic variation in the proportion of individual with infection- or vaccination-derived immunity or a combination of both could have substantial influence on the course of the pandemic. Combined infection/vaccination immunity after break-through infections could ultimately lead to broad immunity also against non-homologous variants.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Swiss National Science Foundation 196644, 196383, NRP (National Research Program) 78 Covid-19 Grant 198412, the Fondation Ancrage Bienfaisance du Groupe Pictet and the private foundation of the University Hospitals of Geneva.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the University Hospitals of Geneva gave ethical approval for the work under the following protocols/numbers: - Understanding COVID study; ethics approval number: CCER 2020-00516, - Persistence study: ethics approval number: CCER 2020-00516 - Collection of sera from variantsEthics approval number: CCER 2020-02323 In addition, anonymized left-over specimens were used under general informed consent of the University Hospitals of Geneva, also approved by the Ethics committee of the University Hospitals of Geneva - CCER ICOVax 2021-00430
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
